Neuphoria Therapeutics Inc. (NasdaqGM: NEUP)
Health Care · Biotechnology · US
$3.30
-1.79% today · -78.7% 1Y
Neuphoria Therapeutics Inc. (NasdaqGM: NEUP) operates in the Biotechnology industry within the Health Care sector. The company is valued at $17.86M and employs 1 people.
Over the last twelve months the share price has lost 78.7%, trading between 3.19 and 17.19.
Tweenvest scores Neuphoria Therapeutics Inc. across four factors: quality 38/100, value 41/100. Its strongest factor is value.
NEUP price history
Not enough price history to draw a chart yet.
Key figures
- Market cap
- $17.86M
- Revenue (TTM)
- $1.17M
- P/E
- —
- EPS
- -3.06
- Dividend yield
- —
- Beta (5Y)
- —
- 52-week high
- $17.19
- 52-week low
- $3.19
- Avg volume (3M)
- —
- Shares outstanding
- 5.41M
- Employees
- 1
- Next earnings
- —
About Neuphoria Therapeutics Inc.
Neuphoria Therapeutics Inc., a clinical stage biopharmaceutical company, develops novel allosteric ion channel modulators for patients with serious central nervous system disorders in Australia. Its lead product candidate is BNC210, an oral, proprietary, selective negative allosteric modulator of the alpha7 nicotinic acetylcholine receptor for post-traumatic stress disorder. The company also develops Merck alpha7 positive allosteric modulators. It has a research collaboration and license agreement with Merck & Co., Inc. to develop alpha7 receptor positive allosteric modulators targeting cognitive dysfunction associated with Alzheimer's disease and other central nervous system conditions. The company was formerly known as Bionomics Limited and changed its name to Neuphoria Therapeutics Inc. in December 2024. Neuphoria Therapeutics Inc. was incorporated in 1996 and is based in Millis, Massachusetts.
- ISIN
- US64136E1029
- Founded
- 1996
- Listed since
- Dec 16, 2021
- Exchange
- Nasdaq Global Market
- Currency
- USD
Other Biotechnology companies
| Company | Market cap | Price | Day |
|---|---|---|---|
| Estrella Immunopharma, Inc.NasdaqCM: ESLA | $18.70M | $0.43 | +4.88% |
| Akari Therapeutics, PlcNasdaqCM: AKTX | $18.69M | $8.18 | -6.73% |
| Kyntra Bio, Inc.NasdaqGS: KYNB | $18.55M | $4.58 | -12.26% |
| Defence Therapeutics Inc.CNSX: DTC | $18.22M | CA$0.34 | -15.00% |
| CCME Global LimitedBSE: 514336 | $17.68M | Rs37.09 | +15.44% |
| Perseus Proteomics Inc.TSE: 4882 | $17.63M | ¥151.00 | -1.31% |
| Marker Therapeutics, Inc.NasdaqCM: MRKR | $17.34M | $1.04 | +7.04% |
| Diamyd Medical AB (publ)OM: DMYD B | $17.06M | Skr1.09 | +11.22% |
Figures last refreshed Oct 18, 2026.